Brandon Sorensen, MD
Interventional Pain Medicine · Visalia, CANPI 1487898938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,292 of the $10,300 with a category attached, or 80.5%. It is spread thinly across 29 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,661 and has fallen 76.4% since, to $863 in 2025.
Across 518 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Collegium Pharmaceutical, Inc.$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$605
- Pfizer$388
- Biohaven Pharmaceutical Holding Company Ltd.$336
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$2,00019%
- Food & beverage$8,29281%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 37 | $2,470 |
| Collegium Pharmaceutical, Inc. | 160 | $2,209 |
| AbbVie(2 entities) | 119 | $1,985 |
| Teva Pharmaceuticals USA, Inc. | 39 | $605 |
| Pfizer | 21 | $388 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $336 |
| Lilly USA, LLC | 16 | $291 |
| Boston Scientific | 13 | $237 |
| Biohaven Pharmaceuticals, Inc. | 10 | $191 |
| Scilex Pharmaceuticals Inc. | 10 | $173 |
| Novartis | 9 | $145 |
| Nevro Corp. | 6 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $131 |
| Biotronik NRO, Inc. | 4 | $130 |
| Arbor Pharmaceuticals, Inc. | 7 | $112 |
| Assertio Therapeutics, Inc. | 9 | $108 |
| Supernus Pharmaceuticals, Inc. | 4 | $94 |
| Amgen | 3 | $94 |
| Biodelivery Sciences International, Inc. | 5 | $90 |
| Pacira Therapeutics, Inc. | 3 | $83 |
| Globus Medical | 3 | $71 |
| Vertex | 3 | $57 |
| Zyla Life Sciences, Inc. | 4 | $46 |
| Nalu Medical, Inc. | 1 | $32 |
| Abbott | 1 | $23 |
| Curonix LLC | 1 | $19 |
| Shionogi Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTORE$2,000
How this compares
$10,300 in reported general payments places this provider in the 75th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 12 | $13,818 |
| LinzessLinaclotide | 11 | $8,941 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 97 | $4,867 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 59 | $1,808 |
| Gabapentin | 88 | $1,384 |
| Diclofenac Sodium | 17 | $890 |
| Oxycodone Hcl | 46 | $742 |
| Morphine Sulfate | 11 | $612 |
| Tizanidine Hcl | 29 | $598 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $598 |
| Cyclobenzaprine Hcl | 49 | $487 |
| Trazodone Hcl | 14 | $444 |
| Duloxetine Hcl | 15 | $314 |
| Ondansetron OdtOndansetron | 17 | $263 |
| Topiramate | 12 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $2,209 | $13,81812 claims |
| AbbVieLinzess | $1,985 | $8,94111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Visalia
- Jonathan GrossmanVisalia$404K
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.